{"transactions":[{"id":1862918,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":112587,"kind":"person","name":"Wilson John Robert","position":1,"cik":"0001755569","reported_name":"Wilson John Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-09T01:33:44.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests on June 6, 2024, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":8000,"derivative":{"exercise_price":1.72,"expiration_date":"2033-06-05","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-23-035615","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919123035615/doc4.xml","form_type":"4"}},{"id":2255700,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":112587,"kind":"person","name":"Wilson John Robert","position":1,"cik":"0001755569","reported_name":"Wilson John Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-26T20:12:40.000Z","date":"2022-05-24","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests on May 24, 2023, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":80000,"derivative":{"exercise_price":0.3377,"expiration_date":"2032-05-23","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001209191-22-032180","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919122032180/doc4.xml","form_type":"4"}},{"id":2674435,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":112587,"kind":"person","name":"Wilson John Robert","position":1,"cik":"0001755569","reported_name":"Wilson John Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-10T22:53:11.000Z","date":"2021-06-08","kind":"grant","acquired":true,"shares":12658,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the portion of the annual board retainer for each non-employee director payable in immediately vested common stock under the Company's 2020 Equity Incentive Plan and based on the closing price of $3.16 per share, on the day immediately preceding the date of the Company's 2021 annual meeting."}],"balance_after":7812008,"source":{"system":"sec-edgar","filing":"0001209191-21-039629","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121039629/doc4.xml","form_type":"4"}},{"id":2693588,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":112587,"kind":"person","name":"Wilson John Robert","position":1,"cik":"0001755569","reported_name":"Wilson John Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-27T20:50:42.000Z","date":"2021-05-25","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option shall vest and become exercisable upon the earlier to occur of (i) May 25, 2022 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":22500,"derivative":{"exercise_price":21.51,"expiration_date":"2031-05-24","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000899243-21-020864","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321020864/doc4.xml","form_type":"4"}},{"id":2779880,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":112587,"kind":"person","name":"Wilson John Robert","position":1,"cik":"0001755569","reported_name":"Wilson John Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-18T20:39:16.000Z","date":"2021-03-16","kind":"purchase","acquired":true,"shares":1714285,"price":1.75,"value":2999998.75,"ownership":{"direct":true},"balance_after":7799350,"source":{"system":"sec-edgar","filing":"0001209191-21-021775","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121021775/doc4.xml","form_type":"4"}},{"id":2794841,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":112587,"kind":"person","name":"Wilson John Robert","position":1,"cik":"0001755569","reported_name":"Wilson John Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-11T21:43:50.000Z","date":"2021-03-11","kind":"sale","acquired":false,"shares":769,"price":31.6277,"value":24321.7013,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.22 to $32.125. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Shares held by the Reporting Person as Trustee of the John R. Wilson Revocable Trust Agreement dated August 3, 2017. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":3164954,"source":{"system":"sec-edgar","filing":"0000899243-21-011155","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321011155/doc4.xml","form_type":"4"}},{"id":2794840,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":112587,"kind":"person","name":"Wilson John Robert","position":1,"cik":"0001755569","reported_name":"Wilson John Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-11T21:43:50.000Z","date":"2021-03-11","kind":"sale","acquired":false,"shares":2308,"price":31.6277,"value":72996.7316,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.22 to $32.125. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Meristem Trust Company, LLC as trustee of the John R. Wilson Irrevocable Trust dated July 9, 2020, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":5412953,"source":{"system":"sec-edgar","filing":"0000899243-21-011155","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321011155/doc4.xml","form_type":"4"}},{"id":2794839,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":112587,"kind":"person","name":"Wilson John Robert","position":1,"cik":"0001755569","reported_name":"Wilson John Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-11T21:43:50.000Z","date":"2021-03-11","kind":"sale","acquired":false,"shares":3397,"price":30.873,"value":104875.581,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.22 to $31.21. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Shares held by the Reporting Person as Trustee of the John R. Wilson Revocable Trust Agreement dated August 3, 2017. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":3165723,"source":{"system":"sec-edgar","filing":"0000899243-21-011155","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321011155/doc4.xml","form_type":"4"}},{"id":2794838,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":112587,"kind":"person","name":"Wilson John Robert","position":1,"cik":"0001755569","reported_name":"Wilson John Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-11T21:43:50.000Z","date":"2021-03-11","kind":"sale","acquired":false,"shares":10188,"price":30.8731,"value":314535.1428,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.22 to $31.21. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Meristem Trust Company, LLC as trustee of the John R. Wilson Irrevocable Trust dated July 9, 2020, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":5415261,"source":{"system":"sec-edgar","filing":"0000899243-21-011155","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321011155/doc4.xml","form_type":"4"}},{"id":2794837,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":112587,"kind":"person","name":"Wilson John Robert","position":1,"cik":"0001755569","reported_name":"Wilson John Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-11T21:43:50.000Z","date":"2021-03-10","kind":"sale","acquired":false,"shares":300,"price":32.3117,"value":9693.51,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.275 to $32.325. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Shares held by the Reporting Person as Trustee of the John R. Wilson Revocable Trust Agreement dated August 3, 2017. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":3169120,"source":{"system":"sec-edgar","filing":"0000899243-21-011155","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321011155/doc4.xml","form_type":"4"}},{"id":2794836,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":112587,"kind":"person","name":"Wilson John Robert","position":1,"cik":"0001755569","reported_name":"Wilson John Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-11T21:43:50.000Z","date":"2021-03-10","kind":"sale","acquired":false,"shares":900,"price":32.3117,"value":29080.53,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.275 to $32.325. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Meristem Trust Company, LLC as trustee of the John R. Wilson Irrevocable Trust dated July 9, 2020, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":5425449,"source":{"system":"sec-edgar","filing":"0000899243-21-011155","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321011155/doc4.xml","form_type":"4"}},{"id":2794835,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":112587,"kind":"person","name":"Wilson John Robert","position":1,"cik":"0001755569","reported_name":"Wilson John Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-11T21:43:50.000Z","date":"2021-03-10","kind":"sale","acquired":false,"shares":8418.75,"price":31.593,"value":265973.56875,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.18 to $32.17. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Shares held by the Reporting Person as Trustee of the John R. Wilson Revocable Trust Agreement dated August 3, 2017. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":3169420,"source":{"system":"sec-edgar","filing":"0000899243-21-011155","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321011155/doc4.xml","form_type":"4"}},{"id":2794834,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":112587,"kind":"person","name":"Wilson John Robert","position":1,"cik":"0001755569","reported_name":"Wilson John Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-11T21:43:50.000Z","date":"2021-03-10","kind":"sale","acquired":false,"shares":25256.25,"price":31.593,"value":797920.70625,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.18 to $32.17. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Meristem Trust Company, LLC as trustee of the John R. Wilson Irrevocable Trust dated July 9, 2020, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":5426349,"source":{"system":"sec-edgar","filing":"0000899243-21-011155","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321011155/doc4.xml","form_type":"4"}},{"id":2794833,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":112587,"kind":"person","name":"Wilson John Robert","position":1,"cik":"0001755569","reported_name":"Wilson John Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-11T21:43:50.000Z","date":"2021-03-10","kind":"sale","acquired":false,"shares":9467.25,"price":30.9284,"value":292806.8949,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.18 to $31.17. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Shares held by the Reporting Person as Trustee of the John R. Wilson Revocable Trust Agreement dated August 3, 2017. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":3177838.75,"source":{"system":"sec-edgar","filing":"0000899243-21-011155","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321011155/doc4.xml","form_type":"4"}},{"id":2794832,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":112587,"kind":"person","name":"Wilson John Robert","position":1,"cik":"0001755569","reported_name":"Wilson John Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-11T21:43:50.000Z","date":"2021-03-10","kind":"sale","acquired":false,"shares":28402.75,"price":30.9283,"value":878448.772825,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.18 to $31.17. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Meristem Trust Company, LLC as trustee of the John R. Wilson Irrevocable Trust dated July 9, 2020, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":5451605.25,"source":{"system":"sec-edgar","filing":"0000899243-21-011155","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321011155/doc4.xml","form_type":"4"}},{"id":2794831,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":112587,"kind":"person","name":"Wilson John Robert","position":1,"cik":"0001755569","reported_name":"Wilson John Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-11T21:43:50.000Z","date":"2021-03-09","kind":"sale","acquired":false,"shares":10169,"price":31.6961,"value":322317.6409,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.58 to $32.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Shares held by the Reporting Person as Trustee of the John R. Wilson Revocable Trust Agreement dated August 3, 2017. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":3187306,"source":{"system":"sec-edgar","filing":"0000899243-21-011155","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321011155/doc4.xml","form_type":"4"}},{"id":2794830,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":112587,"kind":"person","name":"Wilson John Robert","position":1,"cik":"0001755569","reported_name":"Wilson John Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-11T21:43:50.000Z","date":"2021-03-09","kind":"sale","acquired":false,"shares":30506,"price":31.6961,"value":966921.2266,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.58 to $32.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Meristem Trust Company, LLC as trustee of the John R. Wilson Irrevocable Trust dated July 9, 2020, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":5480008,"source":{"system":"sec-edgar","filing":"0000899243-21-011155","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321011155/doc4.xml","form_type":"4"}},{"id":2794829,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":112587,"kind":"person","name":"Wilson John Robert","position":1,"cik":"0001755569","reported_name":"Wilson John Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-11T21:43:50.000Z","date":"2021-03-09","kind":"sale","acquired":false,"shares":17480,"price":31.2959,"value":547052.332,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.58 to $31.57. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Shares held by the Reporting Person as Trustee of the John R. Wilson Revocable Trust Agreement dated August 3, 2017. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":3197475,"source":{"system":"sec-edgar","filing":"0000899243-21-011155","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321011155/doc4.xml","form_type":"4"}},{"id":2794828,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":112587,"kind":"person","name":"Wilson John Robert","position":1,"cik":"0001755569","reported_name":"Wilson John Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-11T21:43:50.000Z","date":"2021-03-09","kind":"sale","acquired":false,"shares":52440,"price":31.2959,"value":1641156.996,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.58 to $31.57. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Meristem Trust Company, LLC as trustee of the John R. Wilson Irrevocable Trust dated July 9, 2020, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":5510514,"source":{"system":"sec-edgar","filing":"0000899243-21-011155","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321011155/doc4.xml","form_type":"4"}},{"id":2864250,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":112587,"kind":"person","name":"Wilson John Robert","position":1,"cik":"0001755569","reported_name":"Wilson John Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-12T22:18:48.000Z","date":"2020-05-19","kind":"grant","acquired":true,"shares":17022,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the portion of the annual board retainer for each non-employee director payable in immediately vested common stock under the\nCompany's 2014 Omnibus Stock Ownership Plan, as amended and based on the closing price of $2.35 per share, on the day immediately\npreceding the date of the Company's 2019 annual meeting."}],"balance_after":6085065,"source":{"system":"sec-edgar","filing":"0001209191-21-010250","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121010250/doc5.xml","form_type":"5"}},{"id":2866811,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":112587,"kind":"person","name":"Wilson John Robert","position":1,"cik":"0001755569","reported_name":"Wilson John Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-12T01:04:06.000Z","date":"2020-12-16","kind":"gift","acquired":true,"shares":3214955,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On December 16, 2020, the Reporting Person transferred 3,214,955 shares of Common Stock to John R. Wilson, as Trustee of the John R. Wilson Revocable Trust Agreement dated August 3, 2017. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":3214955,"source":{"system":"sec-edgar","filing":"0000899243-21-006016","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321006016/doc5.xml","form_type":"5"}},{"id":2866810,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":112587,"kind":"person","name":"Wilson John Robert","position":1,"cik":"0001755569","reported_name":"Wilson John Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-12T01:04:06.000Z","date":"2020-12-16","kind":"gift","acquired":false,"shares":3214955,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-006016","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321006016/doc5.xml","form_type":"5"}},{"id":3066023,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":112587,"kind":"person","name":"Wilson John Robert","position":1,"cik":"0001755569","reported_name":"Wilson John Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-3 Convertible Preferred Stock","published_at":"2020-08-06T10:18:24.000Z","date":"2020-08-03","kind":"exercise","acquired":false,"shares":3499001,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by Meristem Trust Company, LLC as trustee of the John R. Wilson Irrevocable Trust dated July 9, 2020, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2347999},"source":{"system":"sec-edgar","filing":"0000899243-20-021608","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320021608/doc4.xml","form_type":"4"}},{"id":3066022,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":112587,"kind":"person","name":"Wilson John Robert","position":1,"cik":"0001755569","reported_name":"Wilson John Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-3 Convertible Preferred Stock","published_at":"2020-08-06T10:18:24.000Z","date":"2020-08-03","kind":"exercise","acquired":false,"shares":4745943,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3184758},"source":{"system":"sec-edgar","filing":"0000899243-20-021608","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320021608/doc4.xml","form_type":"4"}},{"id":3066021,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":112587,"kind":"person","name":"Wilson John Robert","position":1,"cik":"0001755569","reported_name":"Wilson John Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-08-06T10:18:24.000Z","date":"2020-08-03","kind":"exercise","acquired":true,"shares":2347999,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by Meristem Trust Company, LLC as trustee of the John R. Wilson Irrevocable Trust dated July 9, 2020, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":5562954,"source":{"system":"sec-edgar","filing":"0000899243-20-021608","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320021608/doc4.xml","form_type":"4"}},{"id":3066020,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":112587,"kind":"person","name":"Wilson John Robert","position":1,"cik":"0001755569","reported_name":"Wilson John Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-08-06T10:18:24.000Z","date":"2020-08-03","kind":"exercise","acquired":true,"shares":3184758,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."}],"balance_after":3214955,"source":{"system":"sec-edgar","filing":"0000899243-20-021608","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320021608/doc4.xml","form_type":"4"}},{"id":3072594,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":112587,"kind":"person","name":"Wilson John Robert","position":1,"cik":"0001755569","reported_name":"Wilson John Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-31T22:38:17.000Z","date":"2020-07-29","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) July 29, 2021, and (b) the next annual meeting of the Issuer's stockholders."}],"balance_after":22500,"derivative":{"exercise_price":17,"expiration_date":"2030-07-29","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000899243-20-020918","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320020918/doc4.xml","form_type":"4"}},{"id":3530299,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":112587,"kind":"person","name":"Wilson John Robert","position":1,"cik":"0001755569","reported_name":"Wilson John Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-13T20:02:03.000Z","date":"2019-05-09","kind":"grant","acquired":true,"shares":7260,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the portion of the annual board retainer for each non-employee director payable in immediately vested, common stock under the Company's 2014 Omnibus Stock Ownership Plan, as amended and based on the closing price of $5.51 per share, on the day immediately preceding the date of the Company's 2019 annual meeting."}],"balance_after":6068043,"source":{"system":"sec-edgar","filing":"0001144204-19-025607","document":"tv521408_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000114420419025607/tv521408_4.xml","form_type":"4"}},{"id":3786969,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":112587,"kind":"person","name":"Wilson John Robert","position":1,"cik":"0001755569","reported_name":"Wilson John Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Employee Director Stock Option (Right to Buy)","published_at":"2018-10-19T20:51:37.000Z","date":"2018-10-17","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents options granted under the Company's 2014 Omnibus Stock Ownership Plan, as amended, in connection with the non-employee director compensation program upon appointment as a director of the Company on October 17, 2018.  These shares vest in monthly installments over a two year period.  The option exercise price is the closing price on the date of the grant, October 17, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents options granted under the Company's 2014 Omnibus Stock Ownership Plan, as amended, in connection with the non-employee director compensation program upon appointment as a director of the Company on October 17, 2018.  These shares vest in monthly installments over a two year period.  The option exercise price is the closing price on the date of the grant, October 17, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents options granted under the Company's 2014 Omnibus Stock Ownership Plan, as amended, in connection with the non-employee director compensation program upon appointment as a director of the Company on October 17, 2018.  These shares vest in monthly installments over a two year period.  The option exercise price is the closing price on the date of the grant, October 17, 2018."}],"balance_after":12500,"derivative":{"exercise_price":8.34,"underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001144204-18-054584","document":"tv505078_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000114420418054584/tv505078_4.xml","form_type":"4"}}]}